Autolus Therapeutics (AUTL) vs Lexeo Therapeutics (LXEO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Autolus Therapeutics (AUTL) has outperformed Lexeo Therapeutics (LXEO) over the past year, losing 26.2% versus a loss of 67.3%. Lexeo Therapeutics is the larger company by market cap ($245.1 million vs $241.7 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AUTL | LXEO |
|---|---|---|
| Share price | $0.9073 | $2.96 |
| Market cap | $241.65M | $245.05M |
| 1-day change | -7.38% | +0.34% |
| YTD return | -54.41% | -70.19% |
| 1-year return | -26.24% | -67.33% |
| 5-year return | -85.51% | — |
| EPS (TTM) | $-0.96 | $-1.13 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $75.39M | — |
| Revenue growth (YoY) | +644.94% | — |
| Net income (latest FY) | $-287.53M | $-100.00M |
| Gross margin | -27.83% | — |
| Operating margin | -358.87% | — |
| Net margin | -381.40% | — |
| 52-week high | $2.58 | $10.99 |
| 52-week low | $0.896 | $2.55 |
| Distance from 52-week high | -64.83% | -73.07% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +821.42% | +748.31% |
| Average volume | 2.07M | 1.98M |
| Shares outstanding | 266.34M | 82.79M |
| Employees | 752 | 68 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- AUTL has outperformed LXEO by 41.1 percentage points over the past year.
About Autolus Therapeutics
AUTL stock →Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases in the United Kingdom and internationally. The company offers AUCATZYL, a gene therapy product consisting of autologous T cells that are transduced with a lentiviral vector to express a novel anti-CD19 chimeric antigen receptor.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 752 employees
About Lexeo Therapeutics
LXEO stock →Lexeo Therapeutics, Inc., a clinical stage genetic medicine company, focuses on hereditary and acquired diseases with high unmet need in the United States. Its product pipeline comprises LX2006, an AAVrh10-based gene therapy candidate, which is in phase 1/2 clinical trial to treat friedreich ataxia cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate, which is in phase 1/2 to deliver a functional plakophilin-2 (PKP2) gene to cardiac muscle for the treatment of PKP2-ACM; and LX2021, a gene therapy candidate, which is in preclinical trial to deliver the coding sequence for the functional connexin 43, or Cx43, protein for a group of inherited cardiac muscle disorders associated with a high risk of sudden death, including arrhythmogenic cardiomyopathy (ACM) and certain forms of dilated cardiomyopathy.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 68 employees
AUTL vs LXEO FAQ
Which is bigger, Autolus Therapeutics or Lexeo Therapeutics?
Lexeo Therapeutics (LXEO) is larger, with a market capitalization of $245.05M compared with $241.65M for Autolus Therapeutics (AUTL).
Which stock has performed better over the past year, AUTL or LXEO?
AUTL returned -26.24% over the past 12 months, compared with -67.33% for LXEO (price return, excluding dividends). Past performance does not predict future results.
Are Autolus Therapeutics and Lexeo Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.